Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 14, 2017 17:40 ET | Source: Proteostasis Therapeutics, Inc.

Proteostasis Therapeutics Reports Third Quarter 2017 Results and Provides CF Portfolio Update

Preliminary Data from PTI-428 + Orkambi 28 Day Clinical Study on Track for Q4 2017 Initial Data from PTI-801 + Orkambi 14 Day Clinical Trial Anticipated in Q4 2017 Initial Data from PTI-808 SAD and...
October 31, 2017 16:05 ET | Source: Proteostasis Therapeutics, Inc.

Proteostasis Therapeutics Focuses on Research and Development of CF Drug Candidates and Astellas Pharma Collaboration Programs

CAMBRIDGE, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by...
July 31, 2017 16:16 ET | Source: Proteostasis Therapeutics, Inc

Proteostasis Therapeutics Announces Progression of PTI-428 and PTI-801 to Longer Duration Studies in CF Subjects

PTI-801 Moving to 14 Day Proof of Concept Study in CF Subjects on Orkambi®PTI-428 Continues to Enroll 28 Day Proof of Concept Study in CF Subjects on Orkambi®PTI-808 Investigational New Drug...
July 31, 2017 16:15 ET | Source: Proteostasis Therapeutics, Inc

Proteostasis Appoints Helen M. Boudreau as Chief Financial Officer

CAMBRIDGE, Mass., July 31, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by...
June 29, 2017 07:00 ET | Source: Proteostasis Therapeutics, Inc

Proteostasis Therapeutics Reports Preliminary Data from Phase 1 Study of PTI-428 in Patients with Cystic Fibrosis

CAMBRIDGE, Mass., June 29, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by...
June 23, 2017 07:00 ET | Source: Proteostasis Therapeutics, Inc

Proteostasis Therapeutics Files Investigational New Drug Application for PTI-808, Cystic Fibrosis Potentiator

CAMBRIDGE, Mass., June 23, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by...
June 07, 2017 07:00 ET | Source: Proteostasis Therapeutics, Inc

Proteostasis Therapeutics Announces Clinical and Regulatory Progress Across Pipeline Programs

CAMBRIDGE, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by...
March 30, 2017 16:30 ET | Source: Proteostasis Therapeutics, Inc

Proteostasis Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update

PTI-801 Receives FDA Fast Track Designation; Phase 1 Study Underway IND Submission for PTI-808 Planned for 2Q17 Phase 1 Study of PTI-428 Updated and Ongoing; Results Expected 2Q17 CAMBRIDGE, Mass.,...
November 10, 2016 07:00 ET | Source: Proteostasis Therapeutics, Inc

Proteostasis Therapeutics Reports Third Quarter 2016 Financial Results

CAMBRIDGE, Mass., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by...
October 26, 2016 16:05 ET | Source: Proteostasis Therapeutics, Inc

Proteostasis Therapeutics Announces Conference Call to Provide Clinical and Scientific Update at 30th Annual North American Cystic Fibrosis Conference

CAMBRIDGE, Mass., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right